

Meningococcal Working Group

Carol J. Baker, MD

Advisory Committee on Immunization Practices

February 27, 2008

Working Group Members

- Ciro Sumaya- ACIP
- Richard Clover- AAFP
- Geoff Evans- HRSA
- Penny Dennehy- AAP
- Lucia Lee- FDA
- David Salisbury- UK
- William Shaffner- NFID
- Jon Tempte- AAFP
- Jim Turner- ACHA
- Amy Middleman- SAM
- Martin Luta
- Paul McKinney
- Paul Offit
- Georges Peter
- David Stephens
- Amanda Cohn
- Thomas Clark
- Nancy Messonnier
- Gregory Wallace
- Elaine Miller
- Eric Wientraub

Meningococcal Conjugate Vaccine (MCV4) in 2 – 10 Year Olds

- MCV4 licensed for this age group in October, 2007 in addition to initial licensure for 11 - 55 year olds
- October 2007 ACIP Recommendation
 - 2 - 10 year olds at increased risk of meningococcal disease should be immunized with MCV4 in preference to MPSV4

Objectives of Meningococcal Session

- Presentation on the general use of MCV4 in 2 – 10 year olds
- Working Group does not recommend routine vaccination against meningococcal disease in 2-10 year-olds at this time.

Future Activities

- Revise the 2005 ACIP statement
- Potential for meningococcal conjugate vaccines to be licensed in younger age groups in the near future
- Potential for meningococcal vaccines that include serogroup B